Margaret G. Mcglynn - May 1, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
May 1, 2022
Transactions value $
$0
Form type
4
Date filed
5/3/2022, 04:47 PM
Previous filing
Apr 12, 2022
Next filing
May 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Disposed to Issuer -921 -83.8% 178 May 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Deferred Stock Units Award +921 +19.65% 5.61K May 1, 2022 Common Stock 921 Direct F1, F2
transaction VRTX Stock Option (Right to Buy) Award $0 +4.46K $0.00 4.46K May 1, 2022 Common Stock 4.46K $276.17 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units.
F2 Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death.